HC Wainwright reaffirmed their buy rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $21.00 target price on the stock. HC Wainwright also issued estimates for ORIC Pharmaceuticals’ Q3 2024 earnings at ($0.49) EPS, Q4 2024 earnings at ($0.51) EPS, FY2024 earnings at ($1.83) EPS, Q1 2025 earnings at ($0.53) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.58) EPS and FY2025 earnings at ($2.22) EPS.
Other analysts also recently issued research reports about the stock. Cantor Fitzgerald reissued an overweight rating on shares of ORIC Pharmaceuticals in a research report on Thursday, June 20th. Wedbush reissued an outperform rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a report on Monday, August 12th. Oppenheimer reduced their target price on ORIC Pharmaceuticals from $17.00 to $15.00 and set an outperform rating for the company in a research note on Tuesday, August 13th. Finally, Citigroup dropped their price target on ORIC Pharmaceuticals from $15.00 to $14.00 and set a buy rating on the stock in a research note on Tuesday, May 7th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of Buy and an average target price of $17.60.
View Our Latest Research Report on ORIC
ORIC Pharmaceuticals Stock Performance
Hedge Funds Weigh In On ORIC Pharmaceuticals
Several large investors have recently made changes to their positions in ORIC. AJOVista LLC purchased a new position in ORIC Pharmaceuticals in the fourth quarter valued at $40,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of ORIC Pharmaceuticals by 162.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company’s stock valued at $36,000 after purchasing an additional 3,188 shares in the last quarter. Strs Ohio acquired a new position in ORIC Pharmaceuticals in the 4th quarter worth about $72,000. Quest Partners LLC raised its holdings in ORIC Pharmaceuticals by 253.2% in the 2nd quarter. Quest Partners LLC now owns 10,378 shares of the company’s stock worth $73,000 after purchasing an additional 7,440 shares during the period. Finally, ProShare Advisors LLC purchased a new position in ORIC Pharmaceuticals during the first quarter worth approximately $161,000. 95.05% of the stock is currently owned by institutional investors and hedge funds.
About ORIC Pharmaceuticals
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Recommended Stories
- Five stocks we like better than ORIC Pharmaceuticals
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What Investors Need to Know About Upcoming IPOs
- MarketBeat Week in Review – 8/12 – 8/16
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.